[go: up one dir, main page]

PT1086113E - Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao - Google Patents

Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao

Info

Publication number
PT1086113E
PT1086113E PT99927802T PT99927802T PT1086113E PT 1086113 E PT1086113 E PT 1086113E PT 99927802 T PT99927802 T PT 99927802T PT 99927802 T PT99927802 T PT 99927802T PT 1086113 E PT1086113 E PT 1086113E
Authority
PT
Portugal
Prior art keywords
benzotiepine
utilization
compounds
dioxide derivatives
medicines containing
Prior art date
Application number
PT99927802T
Other languages
English (en)
Inventor
Alfons Enhsen
Heiner Glombik
Wendelin Frick
Hubert Heuer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PT1086113E publication Critical patent/PT1086113E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT99927802T 1998-06-10 1999-05-29 Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao PT1086113E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PT1086113E true PT1086113E (pt) 2004-06-30

Family

ID=7870440

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99927784T PT1086092E (pt) 1998-06-10 1999-05-28 Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao
PT99927802T PT1086113E (pt) 1998-06-10 1999-05-29 Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT99927784T PT1086092E (pt) 1998-06-10 1999-05-28 Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao

Country Status (25)

Country Link
US (1) US6387944B1 (pt)
EP (2) EP1086092B1 (pt)
JP (2) JP4374426B2 (pt)
KR (2) KR100681721B1 (pt)
CN (2) CN1127497C (pt)
AR (2) AR018633A1 (pt)
AT (2) ATE227715T1 (pt)
AU (2) AU753275B2 (pt)
BR (2) BR9912188B1 (pt)
CA (2) CA2334775C (pt)
CZ (2) CZ297989B6 (pt)
DE (3) DE19825804C2 (pt)
DK (2) DK1086092T3 (pt)
ES (2) ES2182535T3 (pt)
HU (2) HU229761B1 (pt)
ID (2) ID28695A (pt)
IL (1) IL140078A (pt)
NO (1) NO327075B1 (pt)
NZ (1) NZ508681A (pt)
PL (2) PL196074B1 (pt)
PT (2) PT1086092E (pt)
RU (2) RU2215001C2 (pt)
TR (2) TR200003634T2 (pt)
WO (2) WO1999064410A1 (pt)
ZA (2) ZA200007060B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
ES2201822T3 (es) 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
OA12654A (en) * 2001-08-22 2006-06-15 Aventis Pharma Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances,and the use thereof.
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MXPA04002179A (es) 2001-09-08 2004-06-29 Astrazeneca Ab Derivados de benzotiazepina y benzotiadiazepina con actividad inhibidora de transporte del acido ileal biliar (ibat) para tratar hiperlipidemia.
WO2003061604A2 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
LT2637668T (lt) 2010-11-04 2016-09-12 Albireo Ab Ibat inhibitoriai kepenų ligoms gydyti
PL2637646T3 (pl) 2010-11-08 2017-01-31 Albireo Ab Kombinacja farmaceutyczna zawierająca inhibitor ibat i środek wiążący kwasy żółciowe
EP2771003B1 (en) 2011-10-28 2017-04-19 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
KR20190135545A (ko) 2011-10-28 2019-12-06 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
WO2014144650A2 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MY209425A (en) 2018-06-20 2025-07-08 Albireo Ab Crystal modifications of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
EP3921027B1 (en) 2019-02-06 2023-07-19 Albireo AB Benzothiazepine compounds and their use as bile acid modulators
HRP20230039T1 (hr) 2019-02-06 2023-06-09 Albireo Ab Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina
JP7562546B2 (ja) 2019-02-12 2024-10-07 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法
TWI865673B (zh) 2019-12-04 2024-12-11 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
EP4551562A1 (en) 2022-07-05 2025-05-14 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
KR20250110930A (ko) 2022-12-09 2025-07-21 알비레오 에이비 신장 질병 치료용 asbt 억제제
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2199944A1 (en) * 1994-09-13 1996-03-21 Len Fang Lee Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
RU2202549C2 (ru) * 1996-03-11 2003-04-20 Джи. Ди. Сирл Энд Ко. Бензотиепины, фармацевтическая композиция на их основе, способ профилактики или лечения гиперлипидемического состояния
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
CA2337307A1 (en) * 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use

Also Published As

Publication number Publication date
AR018633A1 (es) 2001-11-28
CZ297925B6 (cs) 2007-05-02
AR018634A1 (es) 2001-11-28
ES2215387T3 (es) 2004-10-01
HUP0102256A3 (en) 2002-04-29
DE59908522D1 (de) 2004-03-18
CN1305469A (zh) 2001-07-25
RU2215001C2 (ru) 2003-10-27
HUP0102554A1 (hu) 2001-10-28
HUP0102554A3 (en) 2002-12-28
CZ297989B6 (cs) 2007-05-16
ATE227715T1 (de) 2002-11-15
AU753275B2 (en) 2002-10-10
KR20010052701A (ko) 2001-06-25
PL196074B1 (pl) 2007-12-31
IL140078A0 (en) 2002-02-10
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
CN1152039C (zh) 2004-06-02
WO1999064409A2 (de) 1999-12-16
KR20010052682A (ko) 2001-06-25
CZ20004592A3 (cs) 2001-04-11
CA2334775A1 (en) 1999-12-16
ID26876A (id) 2001-02-15
TR200003632T2 (tr) 2001-04-20
ZA200007061B (en) 2001-07-18
BR9912188A (pt) 2001-04-10
AU752633B2 (en) 2002-09-26
JP2002517490A (ja) 2002-06-18
KR100681721B1 (ko) 2007-02-15
PT1086092E (pt) 2003-03-31
NO20006251D0 (no) 2000-12-08
DE19825804C2 (de) 2000-08-24
EP1086113B1 (de) 2004-02-11
ZA200007060B (en) 2001-07-18
HK1039490A1 (en) 2002-04-26
PL344827A1 (en) 2001-11-19
WO1999064410A1 (de) 1999-12-16
CN1127497C (zh) 2003-11-12
BR9911123B1 (pt) 2010-12-14
AU4503199A (en) 1999-12-30
WO1999064409A3 (de) 2000-03-02
JP3374129B2 (ja) 2003-02-04
NZ508681A (en) 2002-06-28
ES2182535T3 (es) 2003-03-01
HUP0102256A1 (hu) 2001-12-28
DK1086113T3 (da) 2004-05-24
CA2334773A1 (en) 1999-12-16
CN1305487A (zh) 2001-07-25
DK1086092T3 (da) 2003-03-10
HU229761B1 (hu) 2014-06-30
DE59903411D1 (de) 2002-12-19
HK1036799A1 (en) 2002-01-18
CA2334773C (en) 2009-05-26
CA2334775C (en) 2009-10-13
BR9911123A (pt) 2006-01-03
HU228570B1 (en) 2013-04-29
JP2002517491A (ja) 2002-06-18
EP1086092B1 (de) 2002-11-13
JP4374426B2 (ja) 2009-12-02
IL140078A (en) 2004-08-31
EP1086113A2 (de) 2001-03-28
AU4501999A (en) 1999-12-30
RU2220141C2 (ru) 2003-12-27
US6387944B1 (en) 2002-05-14
ID28695A (id) 2001-06-28
PL196057B1 (pl) 2007-11-30
EP1086092A1 (de) 2001-03-28
NO20006251L (no) 2001-02-07
NO327075B1 (no) 2009-04-20
BR9912188B1 (pt) 2010-12-14
TR200003634T2 (tr) 2001-06-21
DE19825804A1 (de) 1999-12-16
CZ20004591A3 (cs) 2001-04-11
ATE259372T1 (de) 2004-02-15

Similar Documents

Publication Publication Date Title
PT1086113E (pt) Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao
BR9707839A (pt) Primido-Ú5,4-D¾-primidas medicamentos contendo esses compostos sua aplicação e processo para a sua preparação
PT1169313E (pt) Derivados 1,4-benzotiazepina-1,1-dioxido substituidos com grupos acucar processo para a sua preparacao medicamento contendo estes compostos e sua utilizacao
PT824530E (pt) Derivados de arilglicinamida, processos para a sua producao e preparacoes farmaceuticas contendo estes compostos
PT1117645E (pt) Derivados de propanolamina arilo substituidos metodos para o seu fabrico medicamentos contendo estes compostos e sua utilizacao
BR9708004A (pt) PirimidoÚ5,4¾pirimidinas medicamentos contendo estes compostos seu emprego e processos para sua preparação
BR9912980B1 (pt) Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
BR9810802B1 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto.
IS1950B (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS5130A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
EE9800277A (et) 4-aminopürimidiinderivaadid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
NO20015816D0 (no) Indanylsubstituerte benzenkarbonamider, fremgangsmåter for fremstilling derav, anvendelse derav som medikament ogfarmasöytiske preparater inneholdende disse
PT102291A (pt) Metanossulfonato de paroxetina processos para a sua preparacao composicao farmaceutica contendo o mesmo e sua utilizacao
BRPI9915208B1 (pt) preparados farmacêutico e de comprimido para a aplicação oral compreendendo moxifloxacina e seu processo de preparação.
PT1117661E (pt) Derivados de propanolaminas substituidos com heterociclos, procedimento para a sua preparacao, farmacos contendo estes compostos e a sua aplicacao
PT1073672E (pt) Compostos anti-picornavirus, sua preparacao e utilizacao
PT885204E (pt) Novos derivados de arilglicinamida, processo para a sua preparacao e composicoes farmaceuticas que contem estes compostos
DK1466615T3 (da) Farmaceutisk præparat
PT1165081E (pt) Processo para a preparacao de preparacoes farmaceuticas cintendo tolperisona, para administracao oral
PT1117642E (pt) Derivados de 1,3-diaril-2-piridin-2-il-3(piridin-2-ilamino) -propanol substituidos, procedimentos para a sua preparacao, farmacos contendo estes compostos e a sua aplicacao
PT903339E (pt) Bifenilsulfonilcianamidas processos para a sua preparacao e sua utilizacao como medicamentos
BR9811582B1 (pt) compostos derivados de 4-oxo-3,5-di-hidro-4h-piridazino[4,5-b]indol-1-acetamid a, medicamento e composição farmacêutica contendo os mesmos.
EE9900545A (et) Farmatseutiline kompositsioon
PT1200444E (pt) Novos compostos xantona, sua preparacao e sua utilizacao como medicamento